Summit Therapeutics (SMMT) Operating Expenses (2017 - 2026)

Summit Therapeutics (SMMT) has reported Operating Expenses for 10 consecutive years, with $220.5 million the latest figure, recorded in Q2 2026.

• Quarterly Operating Expenses fell 61.21% year-over-year to $220.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $874.8 million (up 15.22% YoY) and the FY2025 annual result came in at $1.1 billion, up 384.26% from the prior year.
• Operating Expenses climbed to $220.5 million in Q2 2026 per SMMT's latest filing, from $195.2 million in the prior quarter.
• Over the last five years, Operating Expenses for SMMT reached as high as $568.4 million in Q2 2025 and fell as low as $15.8 million in Q2 2023.
• A 5-year average of $135.2 million and a median of $59.0 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses surged 1875.89% — and 2024, when it slumped 92.12%.
• Year by year, Operating Expenses stood at $21.4 million in 2022, then soared by 65.12% to $35.4 million in 2023, then soared by 85.41% to $65.6 million in 2024, then soared by 242.8% to $224.9 million in 2025, then decreased by 1.97% to $220.5 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $220.5 million, $195.2 million, and $224.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.